High Costs of Prostate Cancer Care in Trinidad: A Hospital's Financial Analysis

What is it about?

This study conducted a cost-of-illness analysis over a five-week period at San Fernando General Hospital in Trinidad, focusing on the diagnosis and treatment of prostate cancer. The methodology involved logging and itemizing resources utilized during inpatient admissions, outpatient visits, and surgical procedures, with costs assigned by the hospital's Costing Unit. The scope included outpatient visits, acute presentations, and surgical procedures related to prostate cancer, with data extrapolated to estimate annual costs. Findings revealed that prostate cancer significantly impacts Trinidad's healthcare system, with the annual cost estimated at TTD $14,052,157.66. Outpatient visits, especially those related to diagnostics and management, constituted the majority of the costs, while metastatic disease, though present in fewer cases, contributed disproportionately to overall costs. This study emphasizes the importance of early screening and prevention to mitigate extensive treatment costs and highlights the higher incidence and costs associated with African patients. Policymakers are urged to focus on cost-effective early diagnosis measures to alleviate the economic burden.

Featured Image

Why is it important?

This study investigates the significant economic burden of prostate cancer on the healthcare system in Trinidad and Tobago, particularly at San Fernando General Hospital. Understanding the costs associated with diagnosis and treatment can inform policymakers and healthcare providers about resource allocation and the importance of early intervention. Prostate cancer is the most prevalent cancer and leading cause of cancer-related mortality in Trinidad and Tobago, making This study's insights relevant for public health strategies and budget planning. Key Takeaways: 1. The research demonstrates that prostate cancer diagnosis and treatment impose a substantial financial burden on the Trinidadian healthcare system, with annual costs estimated at TTD $14,052,157.66 (USD $2,066,493). Outpatient visits, particularly those related to screening and diagnosis, constitute the majority of these expenses. 2. Findings reveal that while metastatic cases constitute only 17% of prostate cancer presentations, they account for 32% of the total costs, highlighting the financial impact of advanced-stage disease compared to early detection and intervention. 3. This study highlights the disparity in incidence and cost per patient among different ethnic groups, with African patients presenting more frequently and at advanced stages, resulting in higher treatment costs. This underscores the need for targeted prevention and early screening efforts to reduce disease progression and economic impact.